NIEHS' collaboration with Simulations Plus is part of a national effort to modernize chemical safety assessment through AI-powered new approach methodologies and will continue the application of the ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email pr@fool.com Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

Simulation Plus' total return over-performed the Dow average for my 54 month test period by 390.62%, which is fantastic. Simulation Plus' three-year past CAGR of 25% is well above average and will ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O ...

Earnings call Simulations Plus reported Q2 FY25 revenue of $22.4M, up 23% YoY, with 5% organic growth. Software revenue rose 16% and services 34%, though services were flat organically. Management ...

Simulations Plus, founded in 1996, has established itself as a key player in the bio-simulation market, second only to its larger competitor, Certara (NASDAQ:CERT). The company's business model is ...